Illumina, Inc. (ILMN)
$
99.01
+3.98 (4.02%)
Key metrics
Financial statements
Free cash flow per share
6.5253
Market cap
15.4 Billion
Price to sales ratio
3.5917
Debt to equity
0.9666
Current ratio
1.8077
Income quality
1.2952
Average inventory
556 Million
ROE
0.5313
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis, reflecting its robust operational framework. The earnings per share (EPS) is reported at -$7.69 indicating the company's profitability on a per-share basis, while the net total of other income and expenses is -$346,000,000.00 reflecting non-core financial activities. Operating expenses amount to $3,694,000,000.00 encompassing various operational costs incurred, and the total costs and expenses for the company are $5,205,000,000.00 reflecting its overall spending. Additionally, the weighted average number of shares outstanding is $159,000,000.00 highlighting the company's shareholder base and underscoring its financial health and stability. With a diverse range of products and services, Illumina serves a broad set of customers in genomic research centers, academic institutions, government laboratories, hospitals, and commercial entities in the pharmaceutical, biotechnology, and molecular diagnostics sectors. The company was incorporated in 1998 and is headquartered in San Diego, California, ensuring a strong presence in crucial markets. The stock is reasonably priced at $102.75 appealing to a broad range of investors looking for opportunities in the biotech field. Furthermore, the stock has a high average trading volume of $1,619,212.00 indicating strong liquidity and investor interest. With a mid-range market capitalization of $15,217,837,000.00 the company is a steady performer in the market. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape and driving advances in genetic analysis technologies. Additionally, it belongs to the Healthcare sector, which is experiencing rapid growth and innovation, positioning Illumina as a vital contributor to advancements in life sciences, oncology, and other emerging market segments.
Is Illumina, Inc. (ILMN) a good investment?
Investing in Illumina, Inc. (ILMN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is Illumina, Inc. (ILMN)'s stock forecast?
Analysts predict Illumina, Inc. stock to fluctuate between $68.70 (low) and $156.66 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Illumina, Inc.'s market capitalization?
As of 2025-10-30, Illumina, Inc.'s market cap is $15,217,837,000, based on 153,700,000 outstanding shares.
How does Illumina, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Illumina, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Illumina, Inc. (ILMN) stock?
To buy Illumina, Inc. (ILMN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ILMN. Place an order (Market, Limit, etc.).
What is the best time to invest in Illumina, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Illumina, Inc. stock ever split?
Illumina, Inc.'s last stock split was 2:1 on 2008-09-23.
How did Illumina, Inc. perform in the last earnings report?
Revenue: $4,372,000,000 | EPS: -$7.69 | Growth: -0%.
Where can I find Illumina, Inc.'s investor relations reports?
Visit https://www.illumina.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Illumina, Inc.?
You can explore historical data from here
What is the all-time high and low for Illumina, Inc. stock?
All-time high: $526 (2021-08-16) | All-time low: $68.70 (2025-04-09).
What are the key trends affecting Illumina, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Illumina, Inc. ( ILMN ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Conor Noel McNamara - VP of Investor Relations Jacob Thaysen - CEO & Director Ankur Dhingra - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Douglas Schenkel - Wolfe Research, LLC Vijay Kumar - Evercore ISI Institutional Equities, Research Division Tycho Peterson - Jefferies LLC, Research Division Daniel Leonard - UBS Investment Bank, Research Division Patrick Donnelly - Citigroup Inc., Research Division Mason Carrico - Stephens Inc., Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Jack Meehan - Nephron Research LLC Daniel Brennan - TD Cowen, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Presentation Operator Good day, ladies and gentlemen.
zacks.com
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zacks.com
Illumina (ILMN) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.14 per share a year ago.
seekingalpha.com
Illumina is at a pivotal moment, balancing near-term challenges with innovations in multiomics, AI, and proteomics to redefine its growth trajectory. ILMN's planned SomaLogic acquisition and new AI-driven initiatives like BioInsight strengthen its multiomics strategy and expand high-margin revenue streams. Despite competition and risks from China and regulatory pressures, ILMN maintains strong clinical growth, robust cash flow, and a leading market position.
youtube.com
The Investment Committee give you their top stocks to watch for the second half.
prnewswire.com
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in trial by GeneDx Constellation outperformed orthogonal methods in identifying select difficult-to-map variants SAN DIEGO , Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped read technology, evaluating its performance on regions of the genome that traditional short-read technologies historically have not resolved. GeneDx's early results illustrate the ability of constellation to rapidly identify hard-to-detect variants implicated in rare disease.
zacks.com
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zacks.com
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zacks.com
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
zacks.com
Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.
See all news
